Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).

ABSTRACT: Patients with relapsed/refractory (R/R) follicular lymphoma (FL) have limited effective treatment options. Bruton tyrosine kinase inhibitors (BTKis) increase the anti-tumoural phenotype of tumour-associated macrophages, providing rationale to combine them with rituximab and lenalidomide (R²). Acalabrutinib, a second-generation BTKi, has potential to improve R² efficacy without increasing T-cell-mediated toxicity due to its lack of interleukin-2-inducible T-cell kinase inhibition. Here, we report safety and efficacy from a phase 1b dose-finding study (NCT02180711) evaluating acalabrutinib plus R² in patients with R/R FL. Overall, 29 patients received acalabrutinib plus R² (lenalidomide 15 mg, n = 8; lenalidomide 20 mg, n = 21). At a median acalabr

SUBMITTER: Strati P 

PROVIDER: S-EPMC11886943 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature